Literature DB >> 18764968

Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV.

Robert H Paul1, Thomas Ernst, Adam M Brickman, Constantin T Yiannoutsos, David F Tate, Ronald A Cohen, Bradford A Navia.   

Abstract

In the present study, we examined the relationships among cognitive function, magnetic resonance spectroscopy (MRS) brain metabolite indices measured in the basal ganglia, and quantitative magnetic resonance imaging (MRI) of the caudate nucleus and the putamen in the earliest stages of HIV-related cognitive involvement. Participants included 22 HIV-positive individuals and 20 HIV-negative individuals. HIV-positive individuals performed significantly more poorly than the HIV-negative individuals on several cognitive measures. In addition, the choline/creatine ratio was significantly higher and the N-acetyl aspartate/choline ratio was significantly lower among HIV patients. The caudate and putamen sizes were smaller among HIV-positive patients compared with controls; however, the differences did not reach statistical significance. Correlation analyses revealed associations between cognitive function and select MRS indices. In addition, caudate size was significantly correlated with performances on higher-order thinking tests whereas putamen size was significantly correlated with performances on motor tests. The results suggest that MRS differences are more pronounced than area size differences between seropositive and seronegative individuals in mild stages of HIV-related cognitive impairment. However, basal ganglia size remains an important contributor to cognitive status in this population. Longitudinal studies are needed to determine the evolution of these imaging correlates of HIV-cognitive impairment in HIV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18764968      PMCID: PMC8092588          DOI: 10.1017/S1355617708080910

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  40 in total

1.  Proton MRS and quantitative MRI assessment of the short term neurological response to antiretroviral therapy in AIDS.

Authors:  I D Wilkinson; S Lunn; K A Miszkiel; R F Miller; M N Paley; I Williams; R J Chinn; M A Hall-Craggs; S P Newman; B E Kendall; M J Harrison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

Review 2.  Relationships between cognition and structural neuroimaging findings in adults with human immunodeficiency virus type-1.

Authors:  Robert Paul; Ronald Cohen; Bradford Navia; Karen Tashima
Journal:  Neurosci Biobehav Rev       Date:  2002-05       Impact factor: 8.989

3.  Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men. Multicenter AIDS Cohort Study (MACS).

Authors:  N C Sacktor; R H Lyles; R L Skolasky; D E Anderson; J C McArthur; G McFarlane; O A Selnes; J T Becker; B Cohen; J Wesch; E N Miller
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

4.  CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing.

Authors:  N Sacktor; P M Tarwater; R L Skolasky; J C McArthur; O A Selnes; J Becker; B Cohen; E N Miller
Journal:  Neurology       Date:  2001-08-14       Impact factor: 9.910

5.  Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients.

Authors:  D J Meyerhoff; C Bloomer; V Cardenas; D Norman; M W Weiner; G Fein
Journal:  Neurology       Date:  1999-03-23       Impact factor: 9.910

Review 6.  The AIDS dementia complex: clinical and basic neuroscience with implications for novel molecular therapies.

Authors:  B A Navia; K Rostasy
Journal:  Neurotox Res       Date:  2005-10       Impact factor: 3.911

7.  Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia.

Authors:  L Chang; T Ernst; M Leonido-Yee; M Witt; O Speck; I Walot; E N Miller
Journal:  Neurology       Date:  1999-09-11       Impact factor: 9.910

Review 8.  Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex.

Authors:  Bruce J Brew
Journal:  AIDS       Date:  2004-01-01       Impact factor: 4.177

9.  Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging.

Authors:  I Grant; J H Atkinson; J R Hesselink; C J Kennedy; D D Richman; S A Spector; J A McCutchan
Journal:  Ann Intern Med       Date:  1987-12       Impact factor: 25.391

10.  Cognitive performance after progression to AIDS: a longitudinal study from the Multicenter AIDS Cohort Study.

Authors:  O A Selnes; N Galai; H Bacellar; E N Miller; J T Becker; J Wesch; W Van Gorp; J C McArthur
Journal:  Neurology       Date:  1995-02       Impact factor: 9.910

View more
  49 in total

1.  Independent effects of HIV, aging, and HAART on brain volumetric measures.

Authors:  Beau M Ances; Mario Ortega; Florin Vaida; Jodi Heaps; Robert Paul
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-15       Impact factor: 3.731

2.  Effects of HIV and early life stress on amygdala morphometry and neurocognitive function.

Authors:  Uraina S Clark; Ronald A Cohen; Lawrence H Sweet; Assawin Gongvatana; Kathryn N Devlin; George N Hana; Michelle L Westbrook; Richard C Mulligan; Beth A Jerskey; Tara L White; Bradford Navia; Karen T Tashima
Journal:  J Int Neuropsychol Soc       Date:  2012-05-24       Impact factor: 2.892

3.  Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era.

Authors:  Ronald A Cohen; Jaroslaw Harezlak; Giovanni Schifitto; George Hana; Uraina Clark; Assawin Gongvatana; Robert Paul; Michael Taylor; Paul Thompson; Jeffery Alger; Mark Brown; Jianhui Zhong; Thomas Campbell; Elyse Singer; Eric Daar; Deborah McMahon; Yuen Tso; Constantin T Yiannoutsos; Bradford Navia
Journal:  J Neurovirol       Date:  2010-02       Impact factor: 2.643

Review 4.  Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals.

Authors:  Uraina S Clark; Ronald A Cohen
Journal:  Curr Opin Investig Drugs       Date:  2010-08

5.  Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy.

Authors:  Alan Winston; Chris Duncombe; Patrick C K Li; John M Gill; Stephen J Kerr; Rebekah L Puls; Simon D Taylor-Robinson; Sean Emery; David A Cooper
Journal:  Neuroradiology       Date:  2012-07-07       Impact factor: 2.804

Review 6.  HIV-1 infection alters energy metabolism in the brain: Contributions to HIV-associated neurocognitive disorders.

Authors:  Bianca Cotto; Kalimuthusamy Natarajanseenivasan; Dianne Langford
Journal:  Prog Neurobiol       Date:  2019-05-18       Impact factor: 11.685

Review 7.  Neurocognitive Phenotyping of HIV in the Era of Antiretroviral Therapy.

Authors:  Robert Paul
Journal:  Curr HIV/AIDS Rep       Date:  2019-06       Impact factor: 5.071

8.  Relationship of plasma cytokines and clinical biomarkers to memory performance in HIV.

Authors:  Stephen Correia; Ronald Cohen; Assawin Gongvatana; Skye Ross; James Olchowski; Kathryn Devlin; Karen Tashima; Bradford Navia; Suzanne Delamonte
Journal:  J Neuroimmunol       Date:  2013-09-27       Impact factor: 3.478

Review 9.  Neurologic presentations of AIDS.

Authors:  Elyse J Singer; Miguel Valdes-Sueiras; Deborah Commins; Andrew Levine
Journal:  Neurol Clin       Date:  2010-02       Impact factor: 3.806

Review 10.  Cognitive neuropsychology of HIV-associated neurocognitive disorders.

Authors:  Steven Paul Woods; David J Moore; Erica Weber; Igor Grant
Journal:  Neuropsychol Rev       Date:  2009-05-22       Impact factor: 7.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.